Anxiety and Health-Related Quality of Life Among Patients With Low–Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Results From ECOG Trial E4402 (RESORT)

Podobne zapisy

• Rituximab Extended Schedule or Retreatment Trial (RESORT) for Low Tumor Burden non-Follicular Indolent B-cell Non-Hodgkin Lymphomas: Eastern Cooperative Oncology Group Protocol E4402
  od: Williams, Michael E., i wsp.
  Wydane: (2016)
• Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402
  od: Kahl, Brad S., i wsp.
  Wydane: (2014)
• Response-Adapted Therapy for Aggressive non-Hodgkin's Lymphomas based on early [18F] FDG-PET Scanning: ECOG-ACRIN Cancer Research Group Study (E3404)
  od: Swinnen, Lode J., i wsp.
  Wydane: (2015)
• Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial
  od: Advani, Ranjana H., i wsp.
  Wydane: (2011)
• A Phase II Trial of R-CHOP Followed by Radioimmunotherapy for Early Stage (Stages I/II) Diffuse Large B-Cell Non-Hodgkin Lymphoma: ECOG3402
  od: Witzig, Thomas E., i wsp.
  Wydane: (2015)